| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8239486 | International Journal of Radiation Oncology*Biology*Physics | 2008 | 9 Pages |
Abstract
Fractionated SRS to a dose of 36 Gy in three fractions is well tolerated with gefitinib at daily dose of 250 mg. Further studies of SRS and novel molecular targeted agents are warranted in this challenging clinical setting.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Amanda L. M.D., Denise M. M.D., Brian D. M.D., M.P.H., Laurie. E. M.D., M.B.A., Kevin M.D., Kelly M.S., Changhu M.D.,